The US requirements in the area of pharmaceuticals in the Central American Free Trade Agreement (CAFTA) have been described as "abusive demands" by the Dominican Association of Pharmaceutical Industries (INFADOMI).
In an earlie
r post, FTAs and Public Health, it was reported that negotiations had been delayed over issues regarding data exclusivity and the new pharmaceutical products. In an article in Dominican Today, the changes to the definition of "new product" are a threat to local industry and are in addition to those already specified in the document. This is despite an earlier story, where Hans Hertell (at left), Ambassador to the US, suggested that the impasse over pharmaceuticals and free trade was close to being resolved, and that there would be no further requirements in addition to the original requirements for implementation.
No comments:
Post a Comment